
Pharmacists can improve cardiometabolic adherence by easing adverse effects, simplifying regimens, tackling costs, and synchronizing refills.
Bleeding rates associated with new use of dabigatran (Pradaxa, Boehringer Ingelheim) do not appear to be higher than bleeding rates associated with new use of warfarin, according to an FDA safety review of post-market reports of serious bleeding events.






